1	Comparative performance of between-population vaccine
2	allocation strategies with applications for emerging pandemics
3	
4	Keya Joshi ^{1,*,a} , Eva Rumpler ^{1,*,a} , Lee Kennedy-Shaffer ^{a,b} , Rafia Bosan ^a and Marc Lipsitch ^a
5	
6	^a Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard TH
7	Chan School of Public Health, 02115 Boston, Massachusetts
8	
9	^b Department of Mathematics & Statistics, Vassar College, 12604 Poughkeepsie, New York
10	
11	¹ Contributed equally to this work.
12	*Corresponding authors.
13	
14	
15	
16	
17	

18 **1 Keywords**

19 vaccine allocation, vaccine distribution, emerging pathogen, pandemics

20

21 **2** Abstract

22 Vaccine allocation decisions during emerging pandemics have proven to be challenging due to 23 competing ethical, practical, and political considerations. Complicating decision making, policy 24 makers need to consider vaccine allocation strategies that balance needs both within and between 25 populations. Due to limited vaccine stockpiles, vaccine doses should be allocated in locations where 26 their impact will be maximized. Using a susceptible-exposed-infectious-recovered (SEIR) model we 27 examine optimal vaccine allocation decisions across two populations considering the impact of 28 population size, underlying immunity, continuous vaccine roll-out, heterogeneous population risk 29 structure, and differences in disease transmissibility. We find that in the context of an emerging 30 pathogen where many epidemiologic characteristics might not be known, equal vaccine allocation between populations performs optimally in most scenarios. In the specific case considering 31 32 heterogeneous population risk structure, first targeting individuals at higher risk of transmission or 33 death due to infection leads to equal resource allocation across populations.

34

35 **3 Introduction**

36 In the past two decades, the 2009 H1N1 influenza pandemic and the recent 2019 SARS-CoV-2 37 pandemic have highlighted the need for control and mitigation measures against emerging 38 pathogens. SARS-CoV-2 has caused considerable morbidity and mortality, resulting in over 542 39 million cases and 6.3 million deaths worldwide as of June 2022 (Dong et al., 2020). Previously, the 40 2009 Swine flu pandemic was estimated to have caused around 200 thousand deaths in the first twelve months globally (Dawood et al., 2012; Simonsen et al., 2013). Vaccines are currently the most 41 42 effective public health intervention available against emerging pathogens, and have greatly reduced 43 severe disease outcomes (Watson et al., 2022).

44

45 Even with the approval and availability of vaccines, both the H1N1 and SARS-CoV-2 pandemics have highlighted key challenges in the roll-out and uptake of vaccines globally during an ongoing 46 47 epidemic. During the 2009 H1N1 influenza pandemic, global influenza A vaccine supply was much 48 lower than initially estimated, resulting in large inequities in vaccine access across countries (Fidler, 49 2010; Kaiser Family Foundation, 2009). In the aftermath of the 2009 H1N1 influenza pandemic the 50 World health Organization (WHO) developed a preparedness framework for the sharing of vaccines 51 in a timely manner, and encouraged advance agreements for vaccine allocation and delivery to 52 improve pandemic response globally (Fineberg, 2014; World Health Organization, 2011).

53

54 The COVID-19 pandemic has seen similar challenges, with vaccine supply falling far short of demand. 55 Even with the approval of multiple vaccines, distributed across different regions globally, roll-out has 56 been slow, with vaccination rates highly unequal across countries (Mathieu et al., 2021; Rydland et 57 al., 2022). At the end of 2021, some countries had already vaccinated over 90% of their population, 58 while others did not have access to vaccines (Mathieu et al., 2021). Overall, at the beginning of 59 emerging pandemics, vaccination allocation decisions have been made under the constraint of a 60 limited vaccine stockpile and multiple factors need to be considered to maximize the effect of each 61 dose both within and across populations.

62

Across both pandemics, numerous papers have shown targeting specific subgroups within the
population can result in decreased disease-related morbidity and mortality. For 2009 H1N1
influenza, models found prioritizing individuals at highest risk of complications resulted in the lowest
morbidity and mortality (Chowell et al., 2009; Lee et al., 2010; Tuite et al., 2010). For the 2019 SARS-

CoV-2 pandemic, previous work (Bubar et al., 2021; Hogan et al., 2020; Matrajt et al., 2021) has 67 68 shown, targeting specific subgroups within a given population, including older individuals, results in 69 decreased COVID-19 morbidity and mortality. Other papers looking at health and occupational risk 70 factors (Buckner et al., 2021; Islam et al., 2021) found prioritizing certain occupational groups 71 including healthcare workers, and other essential workers also decreased COVID-19 morbidity and 72 mortality. However, previous theoretical work (Keeling & Shattock, 2012) has also shown that 73 unequal vaccine allocations might be favorable in emerging infectious disease settings, but are less 74 optimal when incorporating realistic assumptions about population heterogeneity and contact 75 structure. This leaves a potentially conflicting message for policy makers when considering optimal 76 allocation strategies. We build upon this work, by not only considering the optimal decision, but also 77 how the decision compares to all possible allocations across two populations. Illustrating these tradeoffs with a simplified model of an emerging pathogen similar to H1N1 or SARS-CoV-2. our 78 79 results show that the efficiency gains for unequal allocations that are found in models with highly 80 simplified epidemics are typically small; moreover, they vanish and can even reverse under settings 81 more relevant to pandemics caused by emerging pathogens. Similar to previous findings, we show in 82 more realistic scenarios, incorporating population heterogeneity and interaction between 83 populations, that equal distributions are not only optimal, but vastly outperform unequal 84 distributions. 85

Materials & Methods 86 4

87 We use a deterministic, two-population, susceptible-exposed-infectious-recovered (SEIR) compartmental model. We assume people are initially susceptible (S). Susceptible individuals move 88 89 to the exposed state (E) after an effective contact with an infectious individual. After a latent period, 90 exposed individuals become infectious (I). After the infectious period has elapsed, infectious 91 individuals move to a recovered state (R). We do not account for waning immunity and assume once 92 individuals have recovered, they stay immune to infection for the duration of our simulation, here 93 modeled as three years. We start by assuming that there is no interaction between the two 94 populations, so all disease transitions happen in parallel between the two populations.

95

96 We extend this SEIR model to allow for underlying immunity (Figure 3, S9) and vaccination (all 97 Figures). At the start of the epidemic, in each population, individuals can be in the susceptible (S), 98 infectious (I), or recovered (R) compartments. When there is underlying immunity, a set proportion 99 of individuals are placed in R. Individuals in R, whether through underlying immunity or infection 100 through the course of the simulation, can never be re-infected. When vaccine doses are distributed to the population, vaccinated individuals are placed in R if the vaccination is successful. We assume 101 102 that the vaccine is all-or-nothing with 95% efficacy, meaning 95% of those who are vaccinated are 103 placed in R and the remainder stay in S. When there is underlying immunity and vaccination, immune 104 individuals may be vaccinated; vaccination has no effect on them, and they remain in R. Finally, we 105 initialize each simulation by placing 0.1% of individuals in I and allow the epidemic to run, 106 unmitigated except by vaccination, through each population. Full model parameters and equations 107 are shown in SI Appendix A.2. Where possible, parameters represent estimates from both the 2009 108 H1N1 influenza pandemic and the 2019 SARS-CoV-2 pandemic; for example, 95% vaccine efficacy is 109 close to that estimated for the Moderna mRNA vaccine Spikevax (Doria-Rose et al., 2021).

110

To recreate the results of Keeling and Shattock (Keeling & Shattock, 2012) we model two 111 112 homogeneous populations with identical characteristics apart from population size. In this scenario 113 we assume population 2 is double the size of population 1 (Figure 2). For later scenarios, which 114 consider the impact of heterogeneity within populations, we simulate two populations that are 115 identical in size, but vary in their population characteristics (e.g., fraction high risk) (Figure 5, S3-S7).

Next, we extend the model by allowing for heterogeneous risk groups. First, within each population,
we model efficient transmitters of infection, for example young adults or children (Goldstein et al.,

119 2021; Kissler et al., 2020) (Figure 5, S3, S4, S6). In this scenario, we assume high-transmitters are

four times more likely to transmit compared to low transmitters (Monod et al., 2021). We fix the

- within-population structure to allow the global R_0 to equal 2, 4, 8 or 16. The full derivation is shown
- in SI Appendix A.2.6. The SEIR model equation are in SI Appendix A.2.4.
- 123

124 Second, we instead model individuals at elevated risk of death from infection (Figure 5, S3, S5, S7). 125 For COVID-19 this can represent, for example, elderly individuals or other individuals with comorbidities known to exacerbate disease (C. Wu et al., 2020; Zhou et al., 2020). For the 2009 H1N1 126 127 influenza pandemic, this represents young adults. For simplicity of the model, we assume these 128 individuals are five times more likely to die than other infected individuals (Lee et al., 2010; Presanis 129 et al., 2009; Williamson et al., 2020). Note that infection fatality rates are assumed to be constant 130 throughout the epidemic, which may not be realistic as health care resources are strained by large 131 caseloads or case management improves over time. The SEIR model equations are in SI Appendix 132 A.2.5.

133

Similar to the homogeneous two-population scenario described above, we initialize the model by placing individuals from each population in the susceptible or recovered state based on the preexisting immunity level and the vaccine allocation scenario. The total number of vaccine doses are split amongst the two populations based on the scenario. Within each population, high-risk individuals are vaccinated first, with leftover doses then allocated to the low-risk population, as described in SI Appendix A.2.7.

140

Finally, we model the scenario where vaccines are unavailable at the start of the epidemic but are progressively rolled out over the course of the epidemic (Figure 4, S4-S7). For this simulation we vary both the timing of roll-out, and the fraction of the population vaccinated each day. We allow vaccine roll-out to start 1, 10, 30, 50, or 100 days after the epidemic has begun and vary the proportion of the population vaccinated from 1% to 3% per day. For these simulations, the vaccine is allocated within and across populations identically to the scenarios described above for the homogeneous and heterogeneous scenarios.

148

For each simulation we calculate the cumulative number of infections and deaths from the deterministic SEIR model at the end of the epidemic. Across each scenario we define the optimal allocation strategy as the one that minimizes the total epidemic size (cumulative number of infections) across both populations. Within the high morbidity scenario, we define the optimal allocation strategy as the one that minimizes the total number of deaths across both populations. This is equivalent to maximizing the total number of people across both populations that escape infection (or death) (Duijzer et al., 2018).

156

157 We conduct sensitivity analyses to assess the robustness of our results. First, we model a leaky 158 vaccine scenario where we assume the vaccine reduces susceptibility to infection for each individual 159 by 95% (Figure S1). As a result, all vaccinated individuals (except those previously immune through 160 natural infection) can become infected with the virus, although the probability of infection for each 161 contact with an infected individual is lower than for an unvaccinated individual. The SEIR model 162 equations are in SI Appendix A.2.3. We further extend the model by relaxing the assumption that the two populations do not interact (Figure S2). We allow a fraction *i* of infected individuals in both 163 164 populations to contribute to the force of infection in the other population instead of their own 165 population. An *i* value of 0 corresponds to no interaction, and an *i* value of 0.5 corresponds to complete interaction between the two populations (i.e. is equivalent to one large population). Next, 166

167 for each of the scenarios above, we additionally consider the impact of varying R_0 between 2 and 16, 168 allowing for improved understanding across a variety of pathogens or viral variants (McMorrow,

169 2021) (Figure). Finally, we relax the assumption of 95% vaccine efficacy by modelling a range of

values from 50% to 90% (Figure S8, S9). Full model equations are shown in SI Appendix A.2.

171 All analyses were conducted in R version 4.0.3.

172

173 **5 Results**

174

175 **5.1 Literature review**

We reviewed the literature on optimal vaccine allocation across populations that was published prior 176 177 to the emergence of SARS-CoV-2 (see SI Table A.3.1). Multiple papers (Forster & Gilligan, 2007; Keeling & Shattock, 2012; Klepac et al., 2011; Rowthorn et al., 2009; J. T. Wu et al., 2007) have shown 178 179 that allocation proportional to population size is rarely optimal. Further, previous studies have 180 highlighted that the timing of vaccine allocation (Matrajt & Longini, 2010; Mylius et al., 2008; 181 Teytelman & Larson, 2013), heterogeneity in population composition, as well as the stochasticity in 182 infection dynamics affect the optimal distribution (Nguyen & Carlson, 2016; Yuan et al., 2015). 183 Duijzer et al. (Duijzer et al., 2018) provide important contributions by showing that the optimal 184 vaccination threshold is often not the herd immunity threshold as further detailed in SI Appendix 185 A.3.2.


186187 **5.2 Optimal allocation in two populations of equal size**

188 We build upon the existing literature by first examining allocation decisions in the simple scenario of 189 two identical, non-interacting populations with no underlying immune protection to the pathogen 190 (see Figure 1). In the simplest case, with a small number of vaccine doses available, pro-rata 191 allocation performs comparably to highly unequal allocation strategies. As the number of vaccine 192 doses increases, highly unequal strategies gain advantage over pro-rata allocation. This occurs 193 because one population can be vaccinated close to, but lower than, its herd immunity threshold, 194 maximizing the indirect effect of the vaccine doses (Duijzer et al., 2018). When sufficient vaccines are 195 available for both populations to reach that threshold, more unequal strategies use the doses less 196 efficiently, as indicated by the increasing arms of the "W" shapes in Figure 1. Allocating doses to the 197 population that has reached its threshold provides limited benefit in that population and withholds 198 doses from the other. When there are nearly enough doses to reach the thresholds in both 199 populations, the optimal strategy becomes equal allocation between the two populations.

200

As the basic reproductive number increases, we again see that unequal allocations preform optimally, as the number of available doses is less than the number needed to reach the critical herd immunity threshold in both populations. In these scenarios, vaccinating one or the other population until it can reach the critical herd immunity threshold results in the lowest cumulative cases across both populations. At very high basic reproductive numbers (i.e., $R_0 = 16$), pro-rata allocation performs

- 206 comparably to highly unequal allocation strategies.
- 207



R0 Value - 2 ---- 8 - - 16

208

209 210 Figure 1: Performance of different allocation strategies of a limited vaccine stockpile across two 211 homogeneous population of equal size with no underlying immunity and prophylactic vaccination. 212 Both populations have one million individuals. Each color represents a different number of total 213 vaccine doses. Each line represents a different basic reproductive number. Each curve shows the cumulative number of cases across both population 1 and 2 for different proportions of doses given 214 215 each population. Across each curve, from left to right, the proportion of doses to population 1 goes 216 from 0 to 100%. Conversely, for population 2, the proportion of doses goes from 100% to 0%. 217

218 **5.3 Optimal allocation in two populations of unequal size**

Extending the simple case of non-interacting populations of equal size, previous studies have shown
how optimal allocation across populations of different sizes is not linear, but varies with the number
of doses available in a characteristic, and often counter-intuitive, "switching" pattern (Duijzer et al.,
2018; Keeling & Shattock, 2012; Klepac et al., 2011).

223


224 As shown in Figure 2 (top), when the number of doses available is very limited, optimal allocation 225 concentrates all vaccine doses to the smallest population, not assigning any to the largest population 226 (regime 1). As the number of doses allocated to the smaller population reaches its threshold, 227 additional doses are gradually allocated to the larger population (regime 2). Strikingly, a drastic 228 switch happens between regimes 2 and 3, and in regime 3 all doses are allocated to the larger 229 population and none to the smaller one. Then, as the largest population itself reaches its threshold, 230 supplementary doses are assigned to the smaller population (regime 4). When the number of vaccines available allows both populations to attain their respective thresholds, vaccines are 231 232 allocated proportionally to the population sizes (regime 5). Note that here we assume that the total 233 number of doses is fixed at the time of allocation and no additional doses become available over time. 234 We relax this assumption in later scenarios considering continuous rollout.

235

For most values of vaccine available, the optimal allocation is highly unequal (regime 1, 2, 3, 4), as previously shown (Duijzer et al., 2018; Keeling & Shattock, 2012). This counterintuitive result is caused by the non-linearity of the indirect effect from each additional vaccine dose. Additional doses are allocated to the population where they have the largest benefit. For example, in regime 1 of Figure 2, additional doses bring a larger benefit in the smaller population then they would in the larger population.

242

243 Importantly, while prior literature (Keeling & Shattock, 2012) demonstrates that unequal allocations 244 can be optimal, these results show that the benefit of such unequal, optimal allocations over more 245 nearly equal ones is often small. As shown in Figure 2 (bottom), for low numbers of vaccine doses (regimes 1 and 2), although concentrating all doses to the smallest population is optimal, other 246 247 strategies do not perform much worse. Each regime is characterized by a different allocation profile 248 that gives rise to a different optimum, indicated by black points. In regime 4, the characteristic W 249 shape appears where a fully unequal allocation is sub-optimal, regardless of which population is 250 vaccinated.



252 253 254 **Figure 2:** Top: Optimal allocation strategies of a limited vaccine stockpile across two homogeneous 255 populations of unequal size with no underlying immunity, prophylactic vaccination and an R_0 of 2. 256 Populations 1 (blue) and 2 (red) have one and two million individuals, respectively. Dashed vertical 257 lines were added to highlight regimes (1 to 5) showing different vaccine allocation patterns. Bottom: 258 Performance of allocation strategies for five different numbers of vaccine doses, representative of the 259 regimes shown in the top half of the Figure. Color coding corresponds to vaccine allocation ranging 260 from giving all doses to population 2 (red) to giving all doses to population 1 (blue). The optimal allocation, the minimal value on each plot, is highlighted by a black point. 261

- 262
- 263

264 **5.4 Impact of underlying immunity**


265 As vaccines become available to different locations at different points in their local epidemic. 266 populations will have varying degrees of underlying immunity to the virus due to prior infections. 267 Serological surveys estimate that at the end of 2020, around a fifth of the population had already been 268 infected in areas hardest hit during the spring of 2020 (23% in NYC (Rosenberg et al., 2020), 18% in 269 London (Public Health England, 2020) and 11% in Madrid and Paris (Pollán et al., 2020; Salje et al., 270 2020)). More recent estimates show seroprevalence increased to almost 60% after the Omicron 271 variant became predominant in the United States (Clarke et al., 2022). Select high-risk groups, 272 including health care workers and nursing home residents, have been shown to have an even higher 273 prevalence of SARS-CoV-2 antibodies (Ladhani et al., 2020). To account for underlying immunity, we 274 further simulate optimal allocation decisions with varying levels of underlying immunity in each 275 population to mirror the fact that allocation decisions are made during an ongoing pandemic.

276

Comparing two populations with varying amounts of underlying immunity, the optimal strategy 277 278 favors prioritizing the population that is closer to their herd immunity threshold (Figure 3). Figure 3 279 shows optimal allocation decisions across two homogeneous populations of equal size with no 280 immunity (top left, repeating Figure 1) or increasing degrees of immunity in population 1. With 281 increasing immunity in population 1, the characteristic V- or W-shape becomes more lopsided as 282 fewer doses are required in population 1 to reach the threshold at which doses should be split 283 between populations. Extremely unequal allocation strategies either waste doses or fail to minimize 284 the cumulative number of infections in both populations if given completely to population 1 or 2. 285 respectively. In addition, allocating vaccines to population 1 beyond the amount needed to reach its threshold results in the highest cumulative number of cases because it confers little additional benefit 286 287 in population 1, and deprives population 2 of vaccines needed to mitigate cases. As before, once the 288 number of doses is large enough to approach or reach the threshold in both populations, optimal 289 strategies move closer to pro-rata allocations.

290

291 As we vary the basic reproductive number, holding vaccine doses fixed, we find the characteristic V 292 and W shapes are shifted to the left. The number of vaccine doses needed to reach the critical herd 293 immunity threshold increases as the basic reproductive number increases. Unequal approaches 294 become more favorable as the level of underlying immunity in population 1 increases, because fewer 295 doses are required for population 1 to reach their herd immunity threshold. Thus, even for very high 296 R_0 values, the optimal strategy, minimizing the cumulative number of cases across both populations, 297 prioritizes allocating doses to the population that is closest to reaching its critical herd immunity 298 threshold.



300 301

Figure 3: Performance of different allocation strategies of a limited vaccine stockpile across two homogeneous populations of equal size (one million individuals) with different underlying immunity, and prophylactic vaccination. We fix population 2 to have no underlying pathogen immunity and vary underlying immunity in population 1 from 0 to 40%. Each color represents a different number of total vaccine doses. Each line represents a different basic reproductive number. The panel on the top

307 left is equivalent to Figure 1.

308

310 **5.5 Impact of delayed vaccine roll-out in a homogeneous population**

Next, we examine the impact of vaccine roll-out over the course of the epidemic. We find both the timing and speed of roll-out play an important role in minimizing the final size of the epidemic. As shown in Figure 4, the cumulative number of cases across both populations is minimized when vaccine roll-out occurs as soon as possible after the start of the epidemic. Further, the final size is minimized when roll-out speed is increased, vaccinating a larger proportion of the population each day.


317

For the early and efficient roll-out (beginning 10 days after the start of the epidemic, at a rate of 2 or 3% of the population/day), the vaccination performance profile across possible allocations looks similar to that of the prophylactic vaccine deployment strategy shown in Figure 1. However, for a slower or more delayed roll-out we see highly unequal approaches perform poorly across almost all doses and more equal approaches result in the smallest final size. This is because a larger fraction of the population is naturally infected, minimizing the gains from concentrating vaccine doses in one population.

325

As we incorporate differences in transmissibility, we find timing and speed to be of greater importance. Even with a vaccine roll-out 50 days after the start of the epidemic, there are no differences in final size across all allocation strategies, within a given R_0 level, as the epidemic has ended in the population before vaccines are introduced. For higher reproductive numbers, faster,

- are needed for vaccination to have an impact on the total number of infections.
- 331



R0 - 2 - 4 - - 8 - - 16

332 333

Figure 4: Performance of different allocation strategies of a limited vaccine stockpile across two homogeneous populations of equal size (one million individuals) with no underlying immunity, with vaccines rolled out at different speeds and different times after the start of the epidemic. Each color represents a different number of total vaccine doses. Each line represents a different basic reproductive number. We vary both the timing and speed of roll-out between 10, 50 or 100 days after the start of the epidemic with 1, 2, or 3% of the population vaccinated per day. Each column represents a given roll-out speed while each row represents a different timing.

342 **5.6 Impact of heterogeneous population structure**

Looking within a population, many studies have shown optimal strategies favor prioritizing older individuals (e.g., those aged 60 or over) or those with certain comorbidities when the goal is minimizing mortality. If the goal instead is minimizing final size, targeting adults 20-49 with an effective transmission-blocking vaccine minimizes cumulative incidence (Bubar et al., 2021; Matrajt et al., 2021). Here we model the impact of heterogeneous population structure to examine the impact of strategies across populations. These simulations consider populations with heterogeneous transmission or with heterogeneous risk of death.

350


Targeting high transmission or high mortality groups first within a population shifts the optimal 351 352 allocation across the two populations towards pro-rata allocation (Figure 5, S3). In Figure 5 we first 353 model the impact of prophylactic vaccination in a heterogeneous population structure with 25% of 354 each population at either high risk of transmission (top) or death (bottom). In the high-transmission 355 scenario, the behavior looks similar to that in Figure 1 for a low number of doses, representing the 356 trade-off between vaccinating the high-transmitters in both populations. Once there are enough 357 doses available to vaccinate enough high-transmitters to reduce transmission dramatically, the 358 optimal strategy favors more pro-rata allocations across the two populations as high-transmitters 359 are driving the bulk of transmission. This shift to more equal allocations occurs at a lower number of 360 vaccine doses compared to Figure 1. In the high-mortality scenario, we see the optimal allocation 361 rapidly shift to pro-rata strategies, starting at a very low number of vaccine doses. Interestingly, the 362 sequence of profiles from Figure 1 is repeated twice. First, for a low number of vaccine doses there is 363 a trade-off between vaccinating the high-mortality individuals in both populations. Then for higher 364 vaccine counts the trade-off is repeated, this time between all individuals of both populations. While 365 this trade-off exists, pro-rata allocation is heavily favored across almost all levels of available vaccine 366 doses.

367

Looking across different levels of R_0 , we find similar trends. Vaccinating higher transmission or mortality groups first results in more equal allocation strategies across populations. For higher R_0 values (i.e., 8 or 16) pro-rata allocation performs comparably to highly unequal strategies. Increasing the proportion of high-risk individuals to 50% of the population (Figure S3) we find similar trends for R_0 values of 2 and 4. For higher R_0 values, unequal approaches perform optimally as a larger fraction of the population is driving transmission, so effectively targeting this group in either population minimizes the cumulative number or deaths or cases across the two populations.

375

376 Next, we considered the impact of continuous roll-out for both the high transmission and high 377 mortality scenarios. We find that across both high-risk scenarios and all vaccine roll-out times and speeds, unequal allocation is highly sub-optimal (Figure S4-S7). Similarly to Figure 4, we vary the 378 379 start date of vaccination roll-out (1, 10, 30, 50, or 100 days), the daily vaccination rate (1, 2 or 3% 380 per day), and the proportion of the population at high risk (25 or 50%). We find that both the speed 381 and timing of vaccine roll-out are important factors in minimizing the cumulative number of cases or 382 deaths across the two populations and see the greatest reduction in cumulative deaths and final size 383 with the earliest and fastest roll-out. Specifically, for vaccine stockpiles larger than 500,000 doses, the achievable impact of vaccination is more dependent on the timing (solid vs. dashed curves) and 384 385 speed (different panels) of vaccine roll-out rather than on the total number of doses available.



386

R0 value - 2 - 4 -- 8 -- 16

Figure 5: Performance of different allocation strategies of a limited vaccine stockpile across two heterogeneous populations of equal size (one million individuals) with no underlying immunity and

389 prophylactic vaccination. Each color represents a different number of total vaccine doses. Each line

390 represents a different basic reproductive number. In both the high transmission scenario (top) and 391 high mortality scenario (bottom), 25% of both populations are high risk.

393 **5.7 Sensitivity Analyses**

We assessed the robustness of our results by varying the characteristics of the vaccine and

- connection between populations to be more representative of the current pandemic. As expected,
 the leaky and all-or-nothing vaccine have the same critical vaccination threshold, though the
- 397 cumulative number of cases in the leaky vaccine scenario is equal to or larger than the all-or -
- 398 nothing scenario (Magpantay et al., 2014) (Figure S1).
- 399

400 In the previous situations we have only considered the scenario of non-interacting populations. As

- 401 we relax this strict assumption, we find that as the amount of interaction between the two 402 populations increases, equal strategies are most favorable (Figure S2). When the force of infection
- 402 populations increases, equal strategies are most favorable (Figure S2). When the force of infection
 403 in each population depends on epidemic dynamics in both populations, accounting for interaction
- 404 drastically changes the optimal allocation profiles and favors equal allocation between populations,
- 405 as seen in previous work (Duijzer et al., 2018; Keeling & Shattock, 2012). Even for low values of the
- 406 interaction parameter *i*, equal allocation rapidly becomes optimal. Indeed, for *i* values higher than
- 407 0.01 which corresponds to one out of every hundred infected individuals contributing to
- 408 infection in the other population equal allocation between the two population always performs
- 409 best. As *i* further increases, unequal strategies progressively approach the optimal (equal)
- allocation as indicated by the flattening of the curves. For *i* equal to 0.5, when the two populations
- 411 concretely behave like one large population, all allocation strategies perform almost identically.
- 412 Compared to the non-interacting case, allowing for interaction between the two populations leads
- to a higher cumulative number of infections for all possible vaccine allocation strategies, and the
- 414 "W"-shaped allocation curve no longer appears.
- 415
- 416 As we increase the basic reproductive number, we find that the optimal strategy quickly favors
- 417 more equal allocation decisions. In addition, interaction between the two populations becomes less
- 418 important for very high values of R₀, as the allocation profiles look similar across all interaction
- 419 parameters for R_0 values of 8 and 16.
- 420
- 421 As vaccine efficacy decreases from 90% to 50%, the cumulative number of cases across both
- 422 populations increases, the critical herd immunity threshold increases and equal-allocation
- 423 strategies become less favorable, with unequal allocations being optimal in some cases for the
- lowest efficacy values. Even for these situations, however, the advantage of unequal allocations are
 modest (Figure S8). Next, as we increase immunity levels across both populations, the total number
- 426 of cases is reduced, and the critical herd immunity threshold is lowered. Even with low vaccine
- 427 efficacy values, in scenarios with high underlying immunity, the critical herd immunity threshold
- 428 can be reached, and equal allocations are favored (Figure S9).
- 429 430

431 6 Discussion

In emerging pandemics, countries must make challenging vaccine allocation decisions due to resource constraints. Previous studies (Keeling & Shattock, 2012) have shown simple scenarios favor unequal allocation. We recreated those findings, and further extend vaccine allocation theory, and apply it to scenarios similar to the 2019 SARS-CoV-2 and 2009 H1N1 influenza pandemics. We focus on these emerging pathogens as those pandemics are the ones for which we have the greatest amount of data, understanding, and for which vaccines were deployed while the pandemic was ongoing.

438

In the simple case of two non-interacting populations of identical size we show that for very high
 quantities of vaccine, relative to population size, equal allocation strategies are optimal. For very few
 doses, all strategies provide comparable results. This supports the European Commission's decision

to allocate vaccine doses proportional to population size among the 27 European Nations (European Commission, 2020). In this simplest model, until there is enough vaccine for both populations to approach their critical herd immunity threshold, optimal strategies favor a highly unequal approach, allocating doses to either population 1 or 2 until the population has reached its threshold. If the populations vary in size, allocation decisions vary, and as the number of vaccines increases, focus switches from the smaller population to the larger one, as supported by Keeling and Shattock (Keeling & Shattock, 2012).

449

450 We consider more realistic scenarios that better mirror the diversity and complexities of emerging 451 pandemics including underlying immunity, population interaction, continuous vaccine roll-out, 452 heterogeneous population structure, and differences in underlying disease transmissibility (either 453 because of biological or social factors). While many of these parameters are either unknown or 454 changing throughout the course of the epidemic, we find that, across a range of scenarios, optimal 455 allocation decisions often favor equal allocation across populations. Since these strategies are often 456 optimal or nearly optimal across a range of parameters, while unequal allocations are only generally 457 optimal for narrow parameter ranges, more pro-rata strategies might be the best option under 458 uncertainty in an ongoing epidemic. Moreover, during an emerging pandemic, it may be unclear 459 whether the newly developed vaccines confer protection against transmission, thus limiting the 460 potential benefit from unequal vaccine allocation strategies that rely on maximizing the benefit from 461 indirect protection in one population. It may thus be preferable to focus on equal allocation strategies 462 as those rely more on the direct protection against disease. Parameter values from COVID-19 and pandemic influenza illustrate this phenomenon; however, these results contribute more generally to 463 464 the existing vaccine allocation theory for any epidemic emerging in multiple populations when key epidemic variables remain unknown. 465

466

467 For scenarios considering heterogeneous population risk, we find that first targeting high risk 468 individuals, either high-transmitters or those at higher risk of death after infection, results in more 469 equal allocations between populations being optimal. Targeting high-risk individuals first, then 470 shifting priority to lower-risk individuals is supported by previous modeling work, looking at SARS-471 CoV-2 vaccine allocations within a single population (Bubar et al., 2021; Chen et al., 2020; Hogan et al., 2020; Matrajt et al., 2021; Moore et al., 2021), and is in concordance with the ongoing COVAX 472 473 strategy, targeting early doses to high-risk individuals, and the USA's implement which vaccinated 474 health care workers and elderly individuals first (Gayle et al., 2020; World Health Organization, 475 2020). This also supports previous guidelines for 2009 H1N1 influenza where vaccines were targeted 476 at high risk groups first, before shifting to the general population (Centers for Disease Control and 477 Prevention, 2009).

478

479 Our modeling analyses are subject to many simplifying assumptions on population dynamics and 480 vaccine characteristics that may not be applicable to the current pandemic. We consider a vaccine 481 that prevents both disease and infection, thus providing indirect protection to a fraction of the 482 population. While some vaccines are able to reduce infectiousness, in future pandemics this effect 483 will still need to be precisely assessed. We do not model vaccine refusal and assume that all 484 individuals given doses accept them. Recent studies (Dror et al., 2020) show vaccine hesitancy as a 485 threat to successful pandemic response. Next, we do not consider delays between doses, but model 486 the epidemic from a final dose which confers 95% efficacy. Due to vaccine shortages, the delay 487 between the first and second dose could impact our findings as individuals may be able to get infected 488 in the interim. Further, we only model one available vaccine. The current SARS-CoV-2 pandemic 489 illustrates how the vaccine landscape can be complex, as multiple vaccines are available, with many 490 more rapidly undergoing testing. Considerations for optimal allocation in this context are more 491 complicated, especially if the vaccines have different immunogenicity profiles, and the quantity of

492 doses and timing of roll-out varies across candidates. Finally, we do not consider the impact of non-493 pharmaceutical interventions (NPIs) in conjunction with vaccination.

494

Furthermore, we only model allocation strategies within two symmetric populations. It is likely that
policy makers will face allocation decisions across multiple countries, or across multiple regions
within a country. While our analyses do not extend to more than two locations, general principles
should remain the same, as illustrated elsewhere for three populations (Keeling & Shattock,
2012) (Duijzer et al., 2018).

500

501 Future modeling work on vaccination strategies during emerging pandemics is needed, for example 502 considering scenarios where multiple vaccine candidates are rolled out simultaneously. These studies should also consider the effects of vaccines on reducing hospitalizations and preserving 503 504 hospital capacity, which may have indirect benefits for mortality rates for COVID-19 and other 505 diseases beyond the direct prevention of infection in high-risk populations. In addition, other work 506 should also consider populations with varying epidemic dynamics, and distribution capacity. Indeed, 507 it has been argued that populations at higher immediate risk of disease spread and populations 508 where vaccine roll-out is most efficient should be prioritized for vaccine allocation (Emanuel & 509 Persad, 2021).

510

511 With vaccine supplies usually severely constrained, in the future rapid allocation decisions will need 512 to be made while the pandemic is ongoing. Due to the global impact and magnitude of some 513 pandemics such as the current 2019 SARS-CoV-2 pandemic, further political and economic 514 constraints will likely play a large role in allocation decisions. Mathematical modelling can provide 515 insight into optimal allocation strategies that maximize the benefit from each dose. Conclusions from 516 such models should be balanced with ethical considerations on the fairness of allocation that also 517 minimize disparities in access. We show key principles that should be considered in the design of 518 realistic and implementable allocation strategies.

519

520 **7** Acknowledgments

521 We thank Dr. Kendall Hoyt for helpful discussions.

522523 8 Funding & Competing Interest

ER, LKS and ML were supported by the Morris-Singer Fund. KJ was supported by NIH Training Grant
2T32AI007535. This work was supported in part by Award Number U01CA261277 from the US
National Cancer Institute of the National Institutes of Health. The content of this article is solely the
responsibility of the authors and does not necessarily represent the official views of the MorrisSinger Fund or the National Institutes of Health.

529

Eva Rumpler, Lee Kennedy-Shaffer, and Rafia Bosan have no conflicts of interest to disclose. KeyaJoshi reports a paid summer internship with Janssen Pharmaceuticals for work unrelated to COVID-

532 19. Marc Lipsitch reports grants from CDC, grants from NIH, grants from UK NIHR, grants from Pfizer,

533 personal fees from Merck, personal fees from Janssen, personal fees from Sanofi Pasteur, personal

- fees from Bristol Myers Squibb, personal fees from Peter Diamandis/Abundance Platinum, outside
 the submitted work; and Unpaid advice to One Day Sooner, Pfizer, Janssen, Astra-Zeneca, COVAX
- 536 (United Biomedical).

537 **References**

- Bubar, K. M., Reinholt, K., Kissler, S. M., Lipsitch, M., Cobey, S., Grad, Y. H., & Larremore, D. B. (2021).
 Model-informed COVID-19 vaccine prioritization strategies by age and serostatus. *Science*, 371(6532), 916–921. https://doi.org/10.1126/science.abe6959
- Buckner, J. H., Chowell, G., & Springborn, M. R. (2021). Dynamic prioritization of COVID-19 vaccines
 when social distancing is limited for essential workers. *Proceedings of the National Academy of Sciences*, *118*(16). https://doi.org/10.1073/pnas.2025786118
- 544 Centers for Disease Control and Prevention. (2009). 2009 H1N1 Vaccine Recommendations.
 545 https://www.cdc.gov/h1n1flu/vaccination/acip.htm
- 546 Chen, X., Li, M., Simchi-Levi, D., & Zhao, T. (2020). Allocation of COVID-19 Vaccines Under Limited
 547 Supply. *MedRxiv*, 2020.08.23.20179820. https://doi.org/10.1101/2020.08.23.20179820
- 548 Chowell, G., Viboud, C., Wang, X., Bertozzi, S. M., & Miller, M. A. (2009). Adaptive Vaccination Strategies
 549 to Mitigate Pandemic Influenza: Mexico as a Case Study. *PLoS ONE*, 4(12), e8164.
 550 https://doi.org/10.1371/journal.pone.0008164
- Clarke, K. E. N., Jones, J. M., Deng, Y., Nycz, E., Lee, A., Iachan, R., Gundlapalli, A. V., Hall, A. J., & MacNeil,
 A. (2022). Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies United States,
 September 2021–February 2022. *MMWR. Morbidity and Mortality Weekly Report*, *71*(17), 606–
 608. https://doi.org/10.15585/mmwr.mm7117e3
- Dawood, F. S., Iuliano, A. D., Reed, C., Meltzer, M. I., Shay, D. K., Cheng, P.-Y., Bandaranayake, D.,
 Breiman, R. F., Brooks, W. A., Buchy, P., Feikin, D. R., Fowler, K. B., Gordon, A., Hien, N. T., Horby,
 P., Huang, Q. S., Katz, M. A., Krishnan, A., Lal, R., ... Widdowson, M.-A. (2012). Estimated global
 mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus
 circulation: a modelling study. *The Lancet Infectious Diseases*, *12*(9), 687–695.
 https://doi.org/10.1016/S1473-3099(12)70121-4
- Dong, E., Du, H., & Gardner, L. (2020). An interactive web-based dashboard to track COVID-19 in real
 time. *The Lancet Infectious Diseases*, 20(5), 533–534. https://doi.org/10.1016/S14733099(20)30120-1
- Doria-Rose, N., Suthar, M. S., Makowski, M., O'Connell, S., McDermott, A. B., Flach, B., Ledgerwood, J.
 E., Mascola, J. R., Graham, B. S., Lin, B. C., O'Dell, S., Schmidt, S. D., Widge, A. T., Edara, V.-V.,
 Anderson, E. J., Lai, L., Floyd, K., Rouphael, N. G., Zarnitsyna, V., ... Kunwar, P. (2021). Antibody
 Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. *New England Journal of Medicine*, 384(23), 2259–2261. https://doi.org/10.1056/NEJMc2103916
- Dror, A. A., Eisenbach, N., Taiber, S., Morozov, N. G., Mizrachi, M., Zigron, A., Srouji, S., & Sela, E. (2020).
 Vaccine hesitancy: the next challenge in the fight against COVID-19. *European Journal of Epidemiology*, *35*(8), 775–779. https://doi.org/10.1007/s10654-020-00671-y
- Duijzer, L. E., van Jaarsveld, W. L., Wallinga, J., & Dekker, R. (2018). Dose-Optimal Vaccine Allocation
 over Multiple Populations. *Production and Operations Management*, 27(1), 143–159.
 https://doi.org/10.1111/poms.12788
- 575 Emanuel, E. J., & Persad, G. (2021, May 24). This Is the Wrong Way to Distribute Badly Needed
 576 Vaccinese. *New York Times*. https://www.nytimes.com/2021/05/24/opinion/vaccine-covid577 distribution.html

- European Commission. (2020). Communication from the Commission EU Strategy for COVID-19
 vaccines. https://ec.europa.eu/info/sites/default/files/communication-eu-strategy-vaccines covid19_en.pdf
- Fidler, D. P. (2010). Negotiating Equitable Access to Influenza Vaccines: Global Health Diplomacy and
 the Controversies Surrounding Avian Influenza H5N1 and Pandemic Influenza H1N1. *PLoS Medicine*, 7(5), e1000247. https://doi.org/10.1371/journal.pmed.1000247
- Fineberg, H. V. (2014). Pandemic Preparedness and Response Lessons from the H1N1 Influenza
 of 2009. New England Journal of Medicine, 370(14), 1335–1342.
 https://doi.org/10.1056/NEJMra1208802
- Forster, G. A., & Gilligan, C. A. (2007). Optimizing the control of disease infestations at the landscape
 scale. *Proceedings of the National Academy of Sciences*, 104(12), 4984–4989.
 https://doi.org/10.1073/pnas.0607900104
- Gayle, H., Foege, W., Brown, L., & Kahn, B. (Eds.). (2020). *Framework for Equitable Allocation of COVID- 19 Vaccine*. National Academies Press. https://doi.org/10.17226/25917
- Goldstein, E., Lipsitch, M., & Cevik, M. (2021). On the Effect of Age on the Transmission of SARS-CoV2 in Households, Schools, and the Community. *The Journal of Infectious Diseases, 223*(3), 362–
 369. https://doi.org/10.1093/infdis/jiaa691
- Hogan, A. B., Winskill, P., Watson, O. J., Walker, P. G., Whittaker, C., Baguelin, M., Haw, D., Lochen, A.,
 Gaythorpe, K. A., Team, I. C.-19 R., Muhib, F., Smith, P., Hauck, K., Ferguson, N. M., & Ghani, A. C.
 (2020). Modelling the allocation and impact of a COVID-19 vaccine. *Imperial College London*.
 https://doi.org/10.25561/82822
- Islam, M. R., Oraby, T., McCombs, A., Chowdhury, M. M., Al-Mamun, M., Tyshenko, M. G., & Kadelka, C.
 (2021). Evaluation of the United States COVID-19 vaccine allocation strategy. *PLOS ONE*, *16*(11),
 e0259700. https://doi.org/10.1371/journal.pone.0259700
- 602Kaiser Family Foundation. (2009). Nine Countries Pledge H1N1 Vaccine Donations To Developing603Countries.604https://www.kff.org/news-summary/nine-countries-pledge-h1n1-vaccine-604donations-to-developing-countries/
- Keeling, M. J., & Shattock, A. (2012). Optimal but unequitable prophylactic distribution of vaccine.
 Epidemics, 4(2), 78–85. https://doi.org/10.1016/j.epidem.2012.03.001
- Kissler, S. M., Viboud, C., Grenfell, B. T., & Gog, J. R. (2020). Symbolic transfer entropy reveals the age
 structure of pandemic influenza transmission from high-volume influenza-like illness data. *Journal of The Royal Society Interface*, 17(164), 20190628.
 https://doi.org/10.1098/rsif.2019.0628
- Klepac, P., Laxminarayan, R., & Grenfell, B. T. (2011). Synthesizing epidemiological and economic
 optima for control of immunizing infections. *Proceedings of the National Academy of Sciences*, *108*(34), 14366–14370. https://doi.org/10.1073/pnas.1101694108
- 614 Ladhani, S. N., Jeffery-Smith, A., Patel, M., Janarthanan, R., Fok, J., Crawley-Boevey, E., Vusirikala, A., Fernandez Ruiz De Olano, E., Perez, M. S., Tang, S., Dun-Campbell, K., Evans, E. W.-, Bell, A., Patel, 615 616 B., Amin-Chowdhury, Z., Aiano, F., Paranthaman, K., Ma, T., Saavedra-Campos, M., ... Zambon, M. 617 (2020). High prevalence of SARS-CoV-2 antibodies in care homes affected by COVID-19: 618 Prospective cohort study, England. EClinicalMedicine, 28, 100597.

- 619 https://doi.org/10.1016/j.eclinm.2020.100597
- Lee, B. Y., Brown, S. T., Korch, G. W., Cooley, P. C., Zimmerman, R. K., Wheaton, W. D., Zimmer, S. M.,
 Grefenstette, J. J., Bailey, R. R., Assi, T.-M., & Burke, D. S. (2010). A computer simulation of vaccine
 prioritization, allocation, and rationing during the 2009 H1N1 influenza pandemic. *Vaccine*,
 28(31), 4875–4879. https://doi.org/10.1016/j.vaccine.2010.05.002
- Magpantay, F. M. G., Riolo, M. A., de Cellès, M. D., King, A. A., & Rohani, P. (2014). Epidemiological
 Consequences of Imperfect Vaccines for Immunizing Infections. *SIAM Journal on Applied Mathematics*, 74(6), 1810–1830. https://doi.org/10.1137/140956695
- Mathieu, E., Ritchie, H., Ortiz-Ospina, E., Roser, M., Hasell, J., Appel, C., Giattino, C., & Rodés-Guirao, L.
 (2021). A global database of COVID-19 vaccinations. *Nature Human Behaviour*, 5(7), 947–953.
 https://doi.org/10.1038/s41562-021-01122-8
- Matrajt, L., Eaton, J., Leung, T., & Brown, E. R. (2021). Vaccine optimization for COVID-19: Who to
 vaccinate first? *Science Advances*, 7(6). https://doi.org/10.1126/sciadv.abf1374
- Matrajt, L., & Longini, I. M. (2010). Optimizing Vaccine Allocation at Different Points in Time during
 an Epidemic. *PLoS ONE*, 5(11), e13767. https://doi.org/10.1371/journal.pone.0013767
- 634McMorrow, M. (2021). Improving communications around vaccine breakthrough and vaccine635effectiveness.636cdn.washingtonpost.com/notes/prod/default/documents/8a726408-07bd-46bd-a945-6373af0ae2f3c37/note/57c98604-3b54-44f0-8b44-b148d8f75165
- 638 Monod, M., Blenkinsop, A., Xi, X., Hebert, D., Bershan, S., Tietze, S., Baguelin, M., Bradley, V. C., Chen, Y., 639 Coupland, H., Filippi, S., Ish-Horowicz, J., McManus, M., Mellan, T., Gandy, A., Hutchinson, M., 640 Unwin, H. J. T., van Elsland, S. L., Vollmer, M. A. C., ... Ratmann, O. (2021). Age groups that sustain resurging COVID-19 epidemics States. 641 in the United Science. 371(6536). 642 https://doi.org/10.1126/science.abe8372
- Moore, S., Hill, E. M., Dyson, L., Tildesley, M. J., & Keeling, M. J. (2021). Modelling optimal vaccination
 strategy for SARS-CoV-2 in the UK. *PLOS Computational Biology*, *17*(5), e1008849.
 https://doi.org/10.1371/journal.pcbi.1008849
- Mylius, S. D., Hagenaars, T. J., Lugnér, A. K., & Wallinga, J. (2008). Optimal allocation of pandemic
 influenza vaccine depends on age, risk and timing. *Vaccine*, *26*(29–30), 3742–3749.
 https://doi.org/10.1016/j.vaccine.2008.04.043
- Nguyen, C., & Carlson, J. M. (2016). Optimizing Real-Time Vaccine Allocation in a Stochastic SIR Model.
 PLOS ONE, *11*(4), e0152950. https://doi.org/10.1371/journal.pone.0152950
- Pollán, M., Pérez-Gómez, B., Pastor-Barriuso, R., Oteo, J., Hernán, M. A., Pérez-Olmeda, M., Sanmartín,
 J. L., Fernández-García, A., Cruz, I., Fernández de Larrea, N., Molina, M., Rodríguez-Cabrera, F.,
 Martín, M., Merino-Amador, P., León Paniagua, J., Muñoz-Montalvo, J. F., Blanco, F., Yotti, R.,
 Blanco, F., ... Vázquez de la Villa, A. (2020). Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a
 nationwide, population-based seroepidemiological study. *The Lancet, 396*(10250), 535–544.
 https://doi.org/10.1016/S0140-6736(20)31483-5
- Presanis, A. M., De Angelis, D., Team3¶, T. N. Y. C. S. F. I., Hagy, A., Reed, C., Riley, S., Cooper, B. S., Finelli,
 L., Biedrzycki, P., & Lipsitch, M. (2009). The Severity of Pandemic H1N1 Influenza in the United
 States, from April to July 2009: A Bayesian Analysis. *PLOS Medicine*, 6(12), e1000207.

660 https://doi.org/10.1371/journal.pmed.1000207

- 661PublicHealthEngland.(2020).Sero-surveillanceofCOVID-19.662https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/888254/COVID19_Epidemiological_Summary_w22_Final.pdf
- Rosenberg, E. S., Tesoriero, J. M., Rosenthal, E. M., Chung, R., Barranco, M. A., Styer, L. M., Parker, M.
 M., John Leung, S.-Y., Morne, J. E., Greene, D., Holtgrave, D. R., Hoefer, D., Kumar, J., Udo, T., Hutton,
 B., & Zucker, H. A. (2020). Cumulative incidence and diagnosis of SARS-CoV-2 infection in New
 York. *Annals of Epidemiology*, *48*, 23-29.e4. https://doi.org/10.1016/j.annepidem.2020.06.004
- Rowthorn, R. E., Laxminarayan, R., & Gilligan, C. A. (2009). Optimal control of epidemics in
 metapopulations. *Journal of The Royal Society Interface*, 6(41), 1135–1144.
 https://doi.org/10.1098/rsif.2008.0402
- Rydland, H. T., Friedman, J., Stringhini, S., Link, B. G., & Eikemo, T. A. (2022). The radically unequal
 distribution of Covid-19 vaccinations: a predictable yet avoidable symptom of the fundamental
 causes of inequality. *Humanities and Social Sciences Communications*, 9(1), 61.
 https://doi.org/10.1057/s41599-022-01073-z
- Salje, H., Tran Kiem, C., Lefrancq, N., Courtejoie, N., Bosetti, P., Paireau, J., Andronico, A., Hozé, N.,
 Richet, J., Dubost, C.-L., Le Strat, Y., Lessler, J., Levy-Bruhl, D., Fontanet, A., Opatowski, L., Boelle,
 P.-Y., & Cauchemez, S. (2020). Estimating the burden of SARS-CoV-2 in France. *Science*,
 369(6500), 208–211. https://doi.org/10.1126/science.abc3517
- Simonsen, L., Spreeuwenberg, P., Lustig, R., Taylor, R. J., Fleming, D. M., Kroneman, M., Van Kerkhove,
 M. D., Mounts, A. W., & Paget, W. J. (2013). Global Mortality Estimates for the 2009 Influenza
 Pandemic from the GLaMOR Project: A Modeling Study. *PLoS Medicine*, *10*(11), e1001558.
 https://doi.org/10.1371/journal.pmed.1001558
- Teytelman, A., & Larson, R. C. (2013). Multiregional Dynamic Vaccine Allocation During an Influenza
 Epidemic. *Service Science*, 5(3), 197–215. https://doi.org/10.1287/serv.2013.0046
- Tuite, A. R., Fisman, D. N., Kwong, J. C., & Greer, A. L. (2010). Optimal Pandemic Influenza Vaccine
 Allocation Strategies for the Canadian Population. *PLoS ONE*, 5(5), e10520.
 https://doi.org/10.1371/journal.pone.0010520
- Watson, O. J., Barnsley, G., Toor, J., Hogan, A. B., Winskill, P., & Ghani, A. C. (2022). Global impact of the
 first year of COVID-19 vaccination: a mathematical modelling study. *The Lancet Infectious Diseases*. https://doi.org/10.1016/S1473-3099(22)00320-6
- Williamson, E. J., Walker, A. J., Bhaskaran, K., Bacon, S., Bates, C., Morton, C. E., Curtis, H. J., Mehrkar,
 A., Evans, D., Inglesby, P., Cockburn, J., McDonald, H. I., MacKenna, B., Tomlinson, L., Douglas, I.
 J., Rentsch, C. T., Mathur, R., Wong, A. Y. S., Grieve, R., ... Goldacre, B. (2020). Factors associated
 with COVID-19-related death using OpenSAFELY. *Nature*, *584*(7821), 430–436.
 https://doi.org/10.1038/s41586-020-2521-4
- 696World Health Organization. (2011). Pandemic influenza preparedness Framework for the sharing of697influenza viruses and access to vaccines and other benefits.698https://apps.who.int/gb/pip/pdf_files/pandemic-influenza-preparedness-en.pdf
- 699World Health Organization. (2020). WHO Concept for fair access and equitable allocation of COVID19700healthproducts.https://www.who.int/docs/default-source/coronaviruse/who-covid19-

- 701 vaccine-allocation-final-working-version-9sept.pdf
- Wu, C., Chen, X., Cai, Y., Xia, J., Zhou, X., Xu, S., Huang, H., Zhang, L., Zhou, X., Du, C., Zhang, Y., Song, J.,
 Wang, S., Chao, Y., Yang, Z., Xu, J., Zhou, X., Chen, D., Xiong, W., ... Song, Y. (2020). Risk Factors
 Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus
 Disease 2019 Pneumonia in Wuhan, China. *JAMA Internal Medicine*, *180*(7), 934.
 https://doi.org/10.1001/jamainternmed.2020.0994
- Wu, J. T., Riley, S., & Leung, G. M. (2007). Spatial considerations for the allocation of pre-pandemic
 influenza vaccination in the United States. *Proceedings of the Royal Society B: Biological Sciences*,
 274(1627), 2811–2817. https://doi.org/10.1098/rspb.2007.0893
- Yuan, E. C., Alderson, D. L., Stromberg, S., & Carlson, J. M. (2015). Optimal Vaccination in a Stochastic
 Epidemic Model of Two Non-Interacting Populations. *PLOS ONE*, *10*(2), e0115826.
 https://doi.org/10.1371/journal.pone.0115826
- Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., Guan, L., Wei, Y., Li, H.,
 Wu, X., Xu, J., Tu, S., Zhang, Y., Chen, H., & Cao, B. (2020). Clinical course and risk factors for
 mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet*, 395(10229), 1054–1062. https://doi.org/10.1016/S0140-6736(20)30566-3